Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of “Buy” from Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $67.75.

Several research analysts have recently issued reports on JSPR shares. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research note on Monday, January 6th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price for the company. HC Wainwright lowered their price target on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Finally, Royal Bank of Canada cut their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in JSPR. JPMorgan Chase & Co. lifted its position in Jasper Therapeutics by 239.8% during the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after buying an additional 11,567 shares during the period. Barclays PLC increased its stake in shares of Jasper Therapeutics by 320.7% during the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after acquiring an additional 12,308 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Jasper Therapeutics during the 3rd quarter worth about $251,000. Wellington Management Group LLP acquired a new stake in shares of Jasper Therapeutics in the third quarter worth approximately $447,000. Finally, State Street Corp grew its holdings in Jasper Therapeutics by 12.3% in the third quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after purchasing an additional 23,564 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Trading Down 2.9 %

Shares of JSPR opened at $5.70 on Friday. Jasper Therapeutics has a twelve month low of $5.25 and a twelve month high of $31.01. The firm has a market capitalization of $85.50 million, a P/E ratio of -1.20 and a beta of 2.18. The firm’s 50-day moving average is $17.66 and its two-hundred day moving average is $19.03.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.15). Analysts predict that Jasper Therapeutics will post -4.47 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.